Also categorized in General:
Late Effects of Treatment for Childhood Cancer (PDQ®)
x hide permanently

Oncolytics Biotech® Inc. Collaborators Present Data from Clinical Study in Multiple Myeloma

PR Newswire

-- All Evaluable Patients to Date See Evidence of an Objective Response; Treatment Combination Associated with Statistically Significant Upregulation of PD-L1--

CALGARYSept. 25, 2015 /CNW/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC) (NASDAQ: ONCY) today announced that Dr. D.W. Sborov and colleagues made a poster presentation at the 15th International Myeloma Workshop (IMW). The poster presentation, entitled "Combination Carfilzomib and the Viral Oncolytic Agent REOLYSIN® in Patients with Relapsed Multiple Myeloma: A Pilot Study Investigating Viral Proliferation," discloses initial findings from a pilot study (NCI-9603) in patients with relapsed or refractory multiple myeloma treated using the combination of carfilzomib ...

Mentions: Oncolytic Viruses PD-1